Press Releases

News from the year: /2013

Notice of Interim Results

Oxford, UK – 27 August, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2020 on Thursday 17 September 2020. A virtual briefing and… Read More

Read more

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

Oxford, UK – 3 August 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture & License Agreement (“DMLA”) with Beam Therapeutics Inc. (“Beam”) (Nasdaq: BEAM), a Cambridge, Mass.-based biotechnology company developing… Read More

Read more

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD

Oxford, UK – 31st July, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a three year Clinical Supply Agreement (“CSA”) with a wholly-owned subsidiary of Axovant Gene Therapies Ltd. (“Axovant”) (Nasdaq: AXGT). The CSA… Read More

Read more

Oxford Biomedica notes interim results from AstraZeneca on AZD1222 showing strong antibody and T-cell responses and acceptable safety profile

Oxford, UK – 20 July, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd (“AstraZeneca”) has announced interim results from the ongoing Phase I/II COV001 trial, led by Oxford University on AZD1222 which showed the SARS-CoV-2… Read More

Read more

Annual General Meeting: Questions and Answers

Annual General Meeting Held at the offices of Oxford Biomedica at Windrush Court, Transport Way, Oxford OX4 6LT on 23 June 2020 at 3.00 p.m. Any questions emailed to us are outlined below Q    What was the process of selecting Dr Roch Doliveux as the new ChairmanA.  … Read More

Read more

Annual General Meeting

Oxford, UK – 23 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today provides details for the Group’s Annual General Meeting (AGM) taking place at the offices of Oxford Biomedica plc, Windrush Court, Transport Way, Oxford OX4 6LT, commencing… Read More

Read more

Information in Relation to Annual General Meeting

Oxford, UK – 19 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today provides further details for the Group’s Annual General Meeting (AGM). As announced on 22 May 2020, Oxford Biomedica is hosting its AGM on Tuesday 23 June… Read More

Read more